COMPANY ANNOUNCEMENT NO. 20-2026 - AARHUS, 12 AUGUST 2026
INSIDE INFORMATION
BioMar Group raises full-year guidance for 2026
Continued commercial momentum and proven ability to navigate raw material market volatility combined with prediction of favourable biological conditions drives BioMar to upgrade its full year guidance for 2026.
For the full year, BioMar now expects:
| Previous 2026 guidance | Updated 2026 guidance | |
| Volumes ('000 tonnes) | 1,600-1,670 | 1,630-1,700 |
| Revenue (DKKm) | 16,000-17,000 | 17,000-18,000 |
| EBIT (DKKm) | 1,100-1,200 | 1,200-1,300 |
| CAPEX (DKKm) | 300-500 | 400-500 |
Volume: The volume growth for 2026 is expected to be stronger than anticipated due to overall good biological conditions, driving higher growth in the segments for Salmon and Selected Species, continuing growth momentum in the Shrimp segment and recent gain on higher shares of contracts and new customers in the Salmon segment. Based on the updated outlook and most recent prospects for volume sales, BioMar increases its volume guidance for 2026 to the 1,630-1,700 thousand tonnes range from previously 1,600-1,670 thousand tonnes.
Revenue: Supported by the updated volume outlook, higher raw material prices, especially for marine ingredients, and current exchange rates, BioMar raises its 2026 revenue guidance to DKK 17.0-18.0 billion from DKK 16.0-17.0 billion previously. BioMar’s revenue is significantly influenced by movements in raw material prices and foreign exchange rates.
EBIT: Based on the updated volume guidance, expected improvement of product- and customer mix, and the ability to navigate and leverage raw material volatility through different nutritional solutions providing higher value, BioMar is substantially upgrading its EBIT guidance to the DKK 1,200-1,300m range from previously DKK 1,100-1,200m.
The updated guidance for revenue and EBIT includes adjusted foreign exchange rate expectations related mainly to the NOK/DKK and AUD/DKK compared to previous guidance and changes to the current exchange rates might have substantial impact on expectations for the year.
CAPEX: Furthermore, the year 2026 is a transition year towards further growth. The investment program is well progressed reducing some uncertainties on both timing and scope. The low-end of CAPEX guidance is increased to reflect good traction of our capacity expansion project in Ecuador to position BioMar for continued growth. The guided CAPEX range is narrowed to DKK 400-500m from previously DKK 300-500m.
The upgraded guidance is based on the Board of Directors’ and the Executive Management’s assessment of the outlook for the Company’s businesses for the rest of the year, including those described in the financial report for the first six months of 2026.
The first half year report for 2026 will be released today following this Company Announcement.
Further Information
BioMar will host a conference call for investors at 13.00 CEST on 13 August 2026, corresponding to 7.00 am EDT. For more information on how to listen, please visit our investor site Home | Investors – BioMar
BioMar Group A/S
Contact details:
Investors/analysts:
Wasiem Husain, VP Investor Relations, Strategy & M&A, BioMar Group A/S, +45 25 75 01 39
Media:
Sif Rishoej, VP People, Purpose & Communication, BioMar Group A/S, +45 23 83 91 71
Forward looking statements: This company announcement contains forward-looking statements about future events. Forward-looking statements are statements (other than statements of historical fact) relating to future events and BioMar’s anticipated or planned financial and operational performance. The words “may”, “will”, “should”, “expect”, “anticipate”, “believe”, “estimate”, “plan”, “project”, “intend”, “target” or variations of these words, including negatives thereof, as well as other statements regarding matters that are not historical facts or regarding future events or prospects, constitute forward-looking statements. BioMar has based any such forward-looking statements on various assumptions including its current views, estimates and projections with respect to future events and financial performance. Although, BioMar believes that these assumptions were reasonable when made, they involve significant known or unknown risks, uncertainties and further assumptions, which could cause actual results to differ materially from the expectations expressed or implied in the forward-looking statements. Forward-looking statements speak as at the date of this announcement and are subject to change without notice, except to the extent required by law.